Cardiovascular and non-cardiovascular safety of dipeptidyl peptidase-4 inhibition: A meta-analysis of randomized controlled cardiovascular outcome trials

Diabetes, Obesity and Metabolism

Volumn 18, Issue 3, 2016, Pages 295-299

  Abbas, A S ^a   Dehbi, H M ^a   Ray, K K ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antidiabetic drug; Cardiovascular disease; DPP IV inhibitor; Meta analysis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PLACEBO; ANTIDIABETIC AGENT;

ACUTE PANCREATITIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DRUG SAFETY; ENZYME INHIBITION; HEART INFARCTION; HUMAN; LETTER; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THROMBOSIS; ADULT; AGED; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DRUG SCREENING; EUROPE; FEMALE; MALE; META ANALYSIS; MIDDLE AGED; PANCREATITIS; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION; EUROPE; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES;

EID: 84957839219     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12595     Document Type: Letter

References (13)

1. Bianchi C, Miccoli R, Daniele G etal. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care 2009; 32(Suppl. 2): S342-S348.
2. Mozaffarian D, Benjamin EJ, Go AS etal. Heart disease and stroke statistics-2015 update: a report from the american heart association. Circulation 2015; 131: e29-e322.
3. Ray KK, Seshasai SR, Wijesuriya S etal. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-1772.
4. Nathan DM, Cleary PA, Backlund JY etal. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
5. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus - evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf. Accessed 6 October 2015.
6. Karagiannis T, Paschos P, Paletas K etal. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ 2012; 344: e1369.
7. Gerrald KR, Van Scoyoc E, Wines RC etal. Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2012; 14: 481-492.
8. Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; 15: 112-120.
9. Patil HR, Al Badarin FJ, Al Shami HA etal. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol 2012; 110: 826-833.
10. Scirica BM, Bhatt DL, Braunwald E etal. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
11. White WB, Cannon CP, Heller SR etal. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
12. Green JB, Bethel MA, Armstrong P etal. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 373: 232-242.
13. Elashoff M, Matveyenko AV, Gier B etal. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156.